Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells

Chien Chih Chiu, Ching Hsiao Li, Man Wai Ung, Tzyy Shiann Fuh, Wei Lun Chen, Kang Fang

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

In this work, we described the proliferation of human non-small-cell-lung- cancer (NSCLC) cells H1437 harboring p53 alleles (proline-267) can be inhibited by low-dosage topoisomerase II inhibitor etoposide (VP-16) in vitro and in vivo. The cytotoxicity was demonstrated by prolonged cell arrest at G2-M checkpoint exhibiting senescence-like phenotype followed by apoptotic cell death that appeared on the sixth day of VP-16 treatment. The experimental in vivo evidence of growth suppression was also demonstrated in xenograft tumors. The appearance of senescence-like state during extended G2-M phase arrest was indicated by slow proliferation and loss of growth sensitivity in culture accompanied with cellular morphological changes, time-dependent regulation of β-galactosidase staining as well as distinct reduction of telomerase activity upon protracted VP-16 exposure. Further molecular determinants leading to G2-M cell arrest was also characterized by the concerted up-regulation of cyclin-dependent kinase inhibitors, p16INK4a and p21Waf1/Cipi, beginning 2 days later following drug exposure at both translational and transcriptional levels, while human telomerase reverse transcriptase (hTERT) activities reduced progressively. The clinically important therapeutic agent VP-16-mediated prolonged cell arrest at G2-M phase prior to apoptotic death offered a different perspective in restraining human cancer cells at low drug dosage, thereby serving as an effective telomerase inhibitor as well as an apoptosis effector. The overall results demonstrated that apoptosis can be regulated differently in human NSCLC cells with disrupted p53. Further effort in elucidating G2-M arrest before leading to apoptosis promises to provide an alternative insight in reversing tumorigenic phenotype of human cancers.

Original languageEnglish
Pages (from-to)249-258
Number of pages10
JournalCancer Letters
Volume223
Issue number2
DOIs
Publication statusPublished - 2005 Jun 8

Fingerprint

Etoposide
Non-Small Cell Lung Carcinoma
Apoptosis
G2 Phase
Telomerase
Cell Division
Galactosidases
Topoisomerase II Inhibitors
Phenotype
Neoplasms
Cyclin-Dependent Kinases
Growth
Heterografts
Proline
Pharmaceutical Preparations
Cell Death
Up-Regulation
Alleles
Staining and Labeling

Keywords

  • Apoptosis
  • Etoposide
  • Human non-small-cell-lung-cancer cells
  • VP-16

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells. / Chiu, Chien Chih; Li, Ching Hsiao; Ung, Man Wai; Fuh, Tzyy Shiann; Chen, Wei Lun; Fang, Kang.

In: Cancer Letters, Vol. 223, No. 2, 08.06.2005, p. 249-258.

Research output: Contribution to journalArticle

Chiu, Chien Chih ; Li, Ching Hsiao ; Ung, Man Wai ; Fuh, Tzyy Shiann ; Chen, Wei Lun ; Fang, Kang. / Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells. In: Cancer Letters. 2005 ; Vol. 223, No. 2. pp. 249-258.
@article{6af4e814aa9b4750ba45235fe42e1436,
title = "Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells",
abstract = "In this work, we described the proliferation of human non-small-cell-lung- cancer (NSCLC) cells H1437 harboring p53 alleles (proline-267) can be inhibited by low-dosage topoisomerase II inhibitor etoposide (VP-16) in vitro and in vivo. The cytotoxicity was demonstrated by prolonged cell arrest at G2-M checkpoint exhibiting senescence-like phenotype followed by apoptotic cell death that appeared on the sixth day of VP-16 treatment. The experimental in vivo evidence of growth suppression was also demonstrated in xenograft tumors. The appearance of senescence-like state during extended G2-M phase arrest was indicated by slow proliferation and loss of growth sensitivity in culture accompanied with cellular morphological changes, time-dependent regulation of β-galactosidase staining as well as distinct reduction of telomerase activity upon protracted VP-16 exposure. Further molecular determinants leading to G2-M cell arrest was also characterized by the concerted up-regulation of cyclin-dependent kinase inhibitors, p16INK4a and p21Waf1/Cipi, beginning 2 days later following drug exposure at both translational and transcriptional levels, while human telomerase reverse transcriptase (hTERT) activities reduced progressively. The clinically important therapeutic agent VP-16-mediated prolonged cell arrest at G2-M phase prior to apoptotic death offered a different perspective in restraining human cancer cells at low drug dosage, thereby serving as an effective telomerase inhibitor as well as an apoptosis effector. The overall results demonstrated that apoptosis can be regulated differently in human NSCLC cells with disrupted p53. Further effort in elucidating G2-M arrest before leading to apoptosis promises to provide an alternative insight in reversing tumorigenic phenotype of human cancers.",
keywords = "Apoptosis, Etoposide, Human non-small-cell-lung-cancer cells, VP-16",
author = "Chiu, {Chien Chih} and Li, {Ching Hsiao} and Ung, {Man Wai} and Fuh, {Tzyy Shiann} and Chen, {Wei Lun} and Kang Fang",
year = "2005",
month = "6",
day = "8",
doi = "10.1016/j.canlet.2004.10.049",
language = "English",
volume = "223",
pages = "249--258",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells

AU - Chiu, Chien Chih

AU - Li, Ching Hsiao

AU - Ung, Man Wai

AU - Fuh, Tzyy Shiann

AU - Chen, Wei Lun

AU - Fang, Kang

PY - 2005/6/8

Y1 - 2005/6/8

N2 - In this work, we described the proliferation of human non-small-cell-lung- cancer (NSCLC) cells H1437 harboring p53 alleles (proline-267) can be inhibited by low-dosage topoisomerase II inhibitor etoposide (VP-16) in vitro and in vivo. The cytotoxicity was demonstrated by prolonged cell arrest at G2-M checkpoint exhibiting senescence-like phenotype followed by apoptotic cell death that appeared on the sixth day of VP-16 treatment. The experimental in vivo evidence of growth suppression was also demonstrated in xenograft tumors. The appearance of senescence-like state during extended G2-M phase arrest was indicated by slow proliferation and loss of growth sensitivity in culture accompanied with cellular morphological changes, time-dependent regulation of β-galactosidase staining as well as distinct reduction of telomerase activity upon protracted VP-16 exposure. Further molecular determinants leading to G2-M cell arrest was also characterized by the concerted up-regulation of cyclin-dependent kinase inhibitors, p16INK4a and p21Waf1/Cipi, beginning 2 days later following drug exposure at both translational and transcriptional levels, while human telomerase reverse transcriptase (hTERT) activities reduced progressively. The clinically important therapeutic agent VP-16-mediated prolonged cell arrest at G2-M phase prior to apoptotic death offered a different perspective in restraining human cancer cells at low drug dosage, thereby serving as an effective telomerase inhibitor as well as an apoptosis effector. The overall results demonstrated that apoptosis can be regulated differently in human NSCLC cells with disrupted p53. Further effort in elucidating G2-M arrest before leading to apoptosis promises to provide an alternative insight in reversing tumorigenic phenotype of human cancers.

AB - In this work, we described the proliferation of human non-small-cell-lung- cancer (NSCLC) cells H1437 harboring p53 alleles (proline-267) can be inhibited by low-dosage topoisomerase II inhibitor etoposide (VP-16) in vitro and in vivo. The cytotoxicity was demonstrated by prolonged cell arrest at G2-M checkpoint exhibiting senescence-like phenotype followed by apoptotic cell death that appeared on the sixth day of VP-16 treatment. The experimental in vivo evidence of growth suppression was also demonstrated in xenograft tumors. The appearance of senescence-like state during extended G2-M phase arrest was indicated by slow proliferation and loss of growth sensitivity in culture accompanied with cellular morphological changes, time-dependent regulation of β-galactosidase staining as well as distinct reduction of telomerase activity upon protracted VP-16 exposure. Further molecular determinants leading to G2-M cell arrest was also characterized by the concerted up-regulation of cyclin-dependent kinase inhibitors, p16INK4a and p21Waf1/Cipi, beginning 2 days later following drug exposure at both translational and transcriptional levels, while human telomerase reverse transcriptase (hTERT) activities reduced progressively. The clinically important therapeutic agent VP-16-mediated prolonged cell arrest at G2-M phase prior to apoptotic death offered a different perspective in restraining human cancer cells at low drug dosage, thereby serving as an effective telomerase inhibitor as well as an apoptosis effector. The overall results demonstrated that apoptosis can be regulated differently in human NSCLC cells with disrupted p53. Further effort in elucidating G2-M arrest before leading to apoptosis promises to provide an alternative insight in reversing tumorigenic phenotype of human cancers.

KW - Apoptosis

KW - Etoposide

KW - Human non-small-cell-lung-cancer cells

KW - VP-16

UR - http://www.scopus.com/inward/record.url?scp=19444371245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19444371245&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2004.10.049

DO - 10.1016/j.canlet.2004.10.049

M3 - Article

C2 - 15896459

AN - SCOPUS:19444371245

VL - 223

SP - 249

EP - 258

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -